AstraZeneca and Daiichi Sankyo have been granted conditional approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer

AstraZeneca and Daiichi Sankyo have been granted conditional approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union and the UK for an additional dosing option, a 1,500mg fixed dose every four weeks, in locally advanced, unresectable non-small
AstraZeneca and Daiichi Sankyo’s Enhertu has been approved in the US for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who
Cobra Biologics, the gene therapy division of the Cognate BioServices’ group, has announced a multi-phase augmentation of its plasmid DNA services as a continuation of its Gene Therapy services’ expansion
BioInvent International has restructured a clinical development agreement with Cancer Research UK (CRUK) for its anti-FcγRIIB antibody, BI-1206. In exchange for a one-time payment, the revised deal simplifies and reduces
The best pharmaceuticals and medical supplies on the market are useless to patients unless they arrive at their destinations intact, unspoiled and on time. The proper packaging and shipping of